Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean J Pittock

Showing results (1-10 of 459) with videos related to

Pageof 46
Sort By:
Lancet (London, England)|August 7, 2007
Interferon beta in multiple sclerosis: how much BENEFIT?Sean J Pittock
Nature Reviews. Neurology|February 6, 2016
Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?Sean J Pittock
The New England Journal of Medicine|March 9, 2002
Unilateral osteoarthritis--"the working hand"Sean J Pittock
Neurology|February 14, 2007
Does benign multiple sclerosis today imply benign multiple sclerosis tomorrow?: implications for treatmentSean J Pittock
The Lancet. Neurology|December 13, 2025
Multiple sclerosis research in 2025: earlier diagnosis and halting progressionSean J Pittock
Neurology|January 27, 2006
Therapeutic decision making in MS: impact of a slower disability progressionSean J Pittock
The Lancet. Neurology|September 15, 2009
Uncertain BENEFIT of early interferon beta-1b treatmentSean J Pittock
Seminars in Neurology|February 8, 2008
Neuromyelitis optica: a new perspectiveSean J Pittock
Handbook of Clinical Neurology|April 27, 2016
Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatmentSean J Pittock, Jacqueline Palace
Acta Neuropathologica|September 23, 2011
Paraneoplastic encephalomyelopathies: pathology and mechanismsAndrew McKeon, Sean J Pittock
Pageof 46

Showing results (1-10 of 459) with videos related to

Sort By:
Pageof 46
Lancet (London, England)|August 7, 2007
Interferon beta in multiple sclerosis: how much BENEFIT?Sean J Pittock
Nature Reviews. Neurology|February 6, 2016
Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?Sean J Pittock
The New England Journal of Medicine|March 9, 2002
Unilateral osteoarthritis--"the working hand"Sean J Pittock
Neurology|February 14, 2007
Does benign multiple sclerosis today imply benign multiple sclerosis tomorrow?: implications for treatmentSean J Pittock
The Lancet. Neurology|December 13, 2025
Multiple sclerosis research in 2025: earlier diagnosis and halting progressionSean J Pittock
Neurology|January 27, 2006
Therapeutic decision making in MS: impact of a slower disability progressionSean J Pittock
The Lancet. Neurology|September 15, 2009
Uncertain BENEFIT of early interferon beta-1b treatmentSean J Pittock
Seminars in Neurology|February 8, 2008
Neuromyelitis optica: a new perspectiveSean J Pittock
Handbook of Clinical Neurology|April 27, 2016
Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatmentSean J Pittock, Jacqueline Palace
Acta Neuropathologica|September 23, 2011
Paraneoplastic encephalomyelopathies: pathology and mechanismsAndrew McKeon, Sean J Pittock
Pageof 46